Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial-Reference-Cited by-同舟云学术

Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial

Published:2024-08 Issue: Volume: Page:
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Solomon George M,Linnemann Rachel W,Rich Rachel,Streby Ashleigh,Buehler Brian,Hunter Eric,Vijaykumar Kadambari,Hunt William R,Brewington John J,Rab Andras,Bai Shasha P,Westbrook Adrianna L,McNicholas-Bevensee Carmel,Hong Jong,Manfredi Candela,Barilla Cristina,Suzuki Shingo,Davis Brian R,Sorscher Eric J

Funder

University of Alabama at Birmingham

Publisher

Elsevier BV

Reference30 articles.

1. Cystic fibrosis genetics: from molecular understanding to clinical application;Cutting;Nat Rev Genet,2015

2. Cystic fibrosis and its management through established and emerging therapies;Spielberg;Annu Rev Genomics Hum Genet,2016

3. Structural mechanisms of CFTR function and dysfunction;Hwang;J Gen Physiol,2018

4. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial;Heijerman;Lancet,2019

5. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele;Middleton;N Engl J Med,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expanding the indication of CFTR modulator combinations for people with cystic fibrosis with non-F508del variants;The Lancet Respiratory Medicine;2024-08